

Stock Code: 603883

Stock Abbreviation: LBX

LBX Pharmacy Chain Joint Stock Company

2026 First Quarter Report

(In case of any discrepancy between the Chinese and English versions of this document, the Chinese version shall prevail.)

The Company's Board of Directors and all directors undertake that nothing hereof contains any false records, misleading representations or major omissions, and are legally liable for authenticity, accuracy and integrity of the contents hereof.

Important Notes

The Board of Directors, the directors and officers of the Company warrant that the contents of this Quarterly Report are true, accurate and complete, free from false records, misleading statements or major omissions, and that they will bear several and joint liability.

The Company's principal, person in charge of accounting work, and person in charge of accounting department (chief accountant) guarantee that the financial information in the quarterly report is true, accurate, and complete.

Whether the first quarter financial statements have been audited

YES NO

I. Main Financial Data

(i) Main Accounting Data and Financial Indicators

Unit: Yuan Currency: RMB

Item	Current reporting period	Same period of previous year	Increase/decrease on a year-on-year basis (%)
Operating income	5,481,296,988	5,435,220,089	0.85
Total profit	385,806,407	366,228,360	5.35
Net profits attributable to shareholders of the listed company	263,855,661	250,636,310	5.27
Net profits attributable to shareholders of the listed company, net of non-recurring profit and loss	260,493,540	243,498,304	6.98
Net cash flows from operating activities	858,596,944	804,266,875	6.76

Basic EPS (RMB/share)	0.35	0.33	5.36
Diluted EPS (RMB/share)	0.35	0.33	5.36
Weighted average return on equity (%)	3.91	3.74	Increase by 0.17%
	End of the reporting period	End of the previous year	Increase/decrease on a year-on-year basis (%)
Total assets	19,907,236,683	19,845,403,504	0.31
Owner's equity attributable to shareholders of the listed company	6,799,247,646	6,535,391,985	4.04

(ii) Non-recurring profit or loss items and amounts

√ Applicable Not Applicable

Unit: Yuan Currency: RMB

Non-recurring profit or loss item	Amount of the current period	Explanation
Gains or losses from the disposal of non-current assets, including the reversal of any previously provided for asset impairment	-1,087,616	
Government grants recognized in the current profit or loss, except for government grants that are closely related to the Company's normal business operations, comply with national policy provisions, are enjoyed according to established standards, and have continuous impacts on the Company's profit or loss	6,902,581	
Except for effective hedging transactions related to the Company's normal business operations, the gains or losses from changes in the fair value of financial assets and liabilities held by non-financial enterprises, as well as gains or losses from the disposal of financial assets and liabilities	6,843	
Fund possession costs that are recorded in current profit or loss and are charged from the non-financial enterprises		
Profit or loss from entrusting others to make investment or management of assets		
Profit or loss from obtaining of entrusted loans		
Various asset losses caused by force majeure factors, such as natural disasters		
Reversal of impairment provision for accounts receivable subject to individual impairment test		
Profits from deficiency of the investment costs for acquisition of the subsidiaries, associates and joint ventures below the fair value of the net identifiable assets received from the investee at the time of investment		
Current net profit or loss of subsidiaries generated from business combinations involving enterprises under common control from the		

beginning of the period to the date of consolidation		
Profit or loss from exchange of non-monetary assets		
Profit or loss from debt restructuring		
One-time expenses incurred by the enterprise due to the discontinuation of related business activities such as expenditures for the resettlement of employees		
One-time impact on the current profit or loss due to adjustments in tax, accounting, and other laws and regulations		
One-time share-based payment expenses recognized due to the cancellation or modification of equity incentive plans		
For cash-settled share-based payments, the gains or losses generated by changes in the fair value of employee compensation payable after the exercise date		
Profit or loss from change in fair value of investment property that is subsequently measured at fair value		
Profits generated from transactions that are obviously unfair in terms of transaction price		
Profit or loss from contingencies that are irrelevant to the normal operation business of the Company		
Trustee fee income from entrusted operation		
Other non-operating income and expenses other than the items listed above	-431,470	
Other profit or loss items that conform to the definition of non-recurring profit or loss		
Less: impact of income tax	533,417	
Influence of minority equity (after-tax)	1,494,800	
Total	3,362,121	

The non-presented items defined as non-recurring profit or loss items at significant amount by the Company according to the Explanatory Announcement No. 1 on Information Disclosure of Companies Issuing Securities to the Public - Non-recurring Profit or Loss, as well as the non-recurring profit or loss items listed in Explanatory Announcement No. 1 on Information Disclosure of Companies Issuing Securities to the Public - Non-recurring Profit or Loss shall be accounted for.

Applicable Not Applicable

(iii) Changes in main accounting data and financial indicators, and reasons

Applicable Not Applicable

II. Shareholder Information

- (i) Total number of ordinary shareholders and preferred shareholders with restored voting rights, and shareholding of top ten shareholders table

Unit: shares

Total number of ordinary shareholders at the end of the reporting period	64,179	Total number of preferred shareholders (shareholders) whose voting rights have been restored at the end of the reporting period	0			
Shareholding of top 10 shareholders (excluding shares lent through securities refinance)						
Name of shareholder	Shareholder nature	Number of shares held	Share holding ratio (%)	Number of restricted shares held	Pledge, mark, or freeze	
					Share status	Quantity
LBX Pharmaceutical Group Co., Ltd.	Domestic Non-State-Owned Legal Person	180,453,475	23.78	0	Pledged	114,140,000
Janstar Investment Limited	Foreign legal person	168,013,035	22.14	0	Pledged	134,410,428
Chen Xiulan	Domestic natural person	13,565,698	1.79	0	None	0
Shi Zhan	Domestic natural person	10,018,811	1.32	0	None	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	8,361,323	1.10	0	None	0
Linzhi Tencent Technology Co., Ltd.	Domestic Non-State-Owned Legal Person	7,391,046	0.97	0	None	0
Zhongtai Securities Co., Ltd. - Huaxia Guozheng FCF Traded Open Index Securities Investment Funds	Others	5,123,900	0.68	0	None	0
China Galaxy Securities Co., Ltd	Others	2,206,300	0.29	0	None	0
Dai Lizhong	Domestic natural person	1,649,778	0.22	0	None	0
Industrial and Commercial Bank of China Limited - Rongtong Health Industry Flexible Hybrid Securities Investment Fund	Others	1,500,000	0.20	0	None	0

Shareholding of top 10 non-restricted shareholders (excluding shares lent through securities refinance)			
Name of shareholder	Number of freely tradable shares held	Type and number of shares	
		Share type	Quantity
LBX Pharmaceutical Group Co., Ltd.	180,453,475	RMB ordinary shares	180,453,475
Janstar Investment Limited	168,013,035	RMB ordinary shares	168,013,035
Chen Xiulan	13,565,698	RMB ordinary shares	13,565,698
Shi Zhan	10,018,811	RMB ordinary shares	10,018,811
Hong Kong Securities Clearing Company Limited	8,361,323	RMB ordinary shares	8,361,323
Linzhi Tencent Technology Co., Ltd.	7,391,046	RMB ordinary shares	7,391,046
Zhongtai Securities Co., Ltd. - Huaxia Guozheng FCF Traded Open Index Securities Investment Funds	5,123,900	RMB ordinary shares	5,123,900
China Galaxy Securities Co., Ltd	2,206,300	RMB ordinary shares	2,206,300
Dai Lizhong	1,649,778	RMB ordinary shares	1,649,778
Industrial and Commercial Bank of China Limited - Rongtong Health Industry Flexible Hybrid Securities Investment Fund	1,500,000	RMB ordinary shares	1,500,000
Description of the relationship or concerted action of the above shareholders	The actual controllers of LBX Pharmaceutical Group Co., Ltd. are Mr. Xie Zilong and Ms. Chen Xiulan (couple). Apart from this, the Company is unaware whether other relationships or concerted actions as defined in the Administrative Measures for the Acquisition of Listed Companies exist among the other shareholders mentioned above.		
Explanation on the participation of top 10 shareholders and top 10 non-restricted shareholders in margin financing, securities lending, and securities refinance business (if any)	Dai Lizhong holds 1,649,778 shares of the Company through a credit account.		

Share lending situation of shareholders holding 5% or more, top 10 shareholders, and top 10 non-restricted circulating shareholders participating in securities refinance business

Applicable Not Applicable

Changes in top 10 shareholders and top 10 non-restricted circulating shareholders compared to the previous period due to lending/return reasons in securities refinance

Applicable Not Applicable

III. Other Reminders

Other important information concerning the Company's operating situation during the reporting period that requires investor attention

Applicable Not Applicable

(I) Core Competitiveness of the Company during the Reporting Period

1. Deployment of wide penetrating pharmaceutical retail network

By expanding its market through deep engagement in direct sales, M&A, franchises and alliances, the Company has built a pharmaceutical retail chain network with wide coverage and deep penetration. As of March 31, 2026, the total number of stores of the Company reached 15,001, covering 18 provincial markets and more than 150 prefecture-level cities and above, including 9,622 direct-sale stores and 5,379 franchise stores. The stores not only cover core city business districts, but also penetrate into community and county markets, demonstrating prominent advantages in scale effect and network synergy.

Continuously focus on advantageous and lower-tier markets, and strengthen localized operation capabilities. As of March 31, 2026, the stores located in advantageous provinces and key cities accounted for 90%. 69% of the new stores in the first quarter of 2026 were concentrated in advantageous provinces and key cities. As of March 31, 2026, the stores in prefecture-level cities and below accounted for 78%. Among the new stores in the first quarter of 2026, the in prefecture-level cities and below accounted for 84%.

2. Eco-empowered franchise alliance asset-light expansion

(1) Improve both quality and efficiency of the franchise business, and highlight the advantages of asset-light expansion

Deepen asset-light operations and optimize franchise structure. For single stores, the replicability of the profit model was strengthened through refined location selection, standardized procedures, full-cycle assistance and digital empowerment. For projects, coordinate regional resources to achieve multi-store synergy and enhance the scale effect. In the first quarter of 2026, the franchise of old stores accounted for 85.6%, representing a year-on-year increase of 23.1%. The overall development of the franchise business was steady, and the distribution sales of the franchise business in the first quarter of 2026 approximately amounted to RMB 609.31 million, representing a year-on-year increase of 4.9%.

(2) Improve the business ecology of alliances and steadily build a reserve pool for M&A

The alliance business concentrates on pharmaceutical retail operation services and export of goods, and extensive cooperation is conducted. By the end of the first quarter of 2026, it had covered 29 provinces and cities, and there had been 22,768 alliance stores (not included in the total number of stores). In the first quarter of 2026, the alliance distribution sales amounted to RMB 72 million. The Company listed high-quality alliance enterprises as potential M&A targets, and accelerated the planning of equity participation. At the end of the first quarter of 2026, the Company had cumulatively owned 233

shareholding partners, corresponding to a retail scale of RMB 13.43 billion, and 11,425 stores, which accounted for 42% of all partners. Sufficient reserves of high-quality M&A targets were made.

3. "Professional" + "warm" services, and over 10,000 chronic disease management pharmacies

(1) Transformation of stores from being "transaction-based" to be "relationship-based"

The "relationship-based" store services focus on key links such as self-assessment of chronic diseases and follow-up on return visits. They highlight service process and customer experience. Through systematic training, the Company has promoted the comprehensive transformation of employees from psychological cognition to service capability. It takes customer needs as the starting point and foothold of decision-making and operation, and wins long-term trust through dedicated services to realize the transformation into customer relationship partners. In the first quarter of 2026, more than 300 "relationship-based" benchmark stores were newly opened, and the Company had a total of 701 "relationship-based" benchmark stores.

(2) Upgrading professional chronic disease services and improving health management system

Promote the transformation of chronic disease service model from being "drug-centered" to be "user-centered". Firstly, 10,000 stores across the country are equipped with self-testing equipment for chronic diseases covering five core indicators: blood sugar, blood pressure, blood uric acid, blood lipids and heart rate. Secondly, maintain dynamic electronic health records with the aid of digital tools such as "AI-based Blood Pressure and Blood Sugar Interpretation Report". Thirdly, the stores are equipped with a pharmaceutical service teams, where licensed pharmacists are the core members, to improve professional services by "promoting learning through competitions". By the end of the first quarter, the Company had maintained health records for 23.28 million members with chronic diseases, provided health self-testing services for more than 150 million times, and accumulated 44.04 million return visits.

(3) Improving the membership operation system

The Company has continuously improved its membership business strategy, driving the increase in both the membership scale and the value of the whole lifecycle through refined operation and equity upgrading. At the end of the first quarter of 2026, the Company had owned 110.4 million members (including franchise). The number of active members in the first quarter was 15.35 million, and the number of newly registered members during the reporting period was 1.91 million, accounting for 74.1% of the membership sales.

4. Leading medical insurance qualification, and professional customer redirection for undertaking outflow prescriptions

(1) Continuously strengthening professional attributes to attract customers and undertake outflow prescriptions

Build professional pharmacies up to high standards and give priority to undertaking outflow prescriptions. During the reporting period, the Company focused on strengthening its professional service capabilities and actively showed care for breast cancer, skin diseases, leukemia, lung cancer, hemophilia and other diseases. As of the end of the reporting period, the Company had owned 13,492 stores with medical insurance qualification, including 8,965 direct-sale stores and 4,527 franchised stores with the qualification, and among the direct-sale stores, the stores with medical insurance qualification accounted

for 93.17%. The Company owned 4,514 overall qualified stores. A total of 1,745 stores of the Company obtained the designated qualification for "outpatient chronic diseases", and 318 stores held dual-channel qualifications.

(2) Improving quality and efficiency of medical insurance business and laying a solid foundation for compliance operation

Firstly, optimize prescription settlement procedures and improve the performance of the settlement system. In the first quarter, the Group implemented unified medical insurance-based prescription procedures, clearly defined the boundary of responsibilities for each position, and cleared obstacles to full-link execution. Besides, the Group guarantees more stable, efficient and reliable system operation, effectively improving customers' drug purchasing experience and service efficiency. Secondly, strengthen the compliance system. Improve standard management procedures adapted to the whole country, and build a sound regulatory response system. Thirdly, improve the drug traceability management capability, to truly realize the traceability of drug circulation information, and guarantee medication safety.

5. Fully digital and intelligent retail pharmacies for empowering efficient operations

(1) Improving the application of AI technology

Iteratively optimize "LBX AI". Utilizing the accumulated operational experience and data assets, the Company has strengthened the "LBX AI's" understanding of business knowledge through targeted training, and output more forward-looking and accurate business decision analysis. A low-code AI agent development and sharing platform has been built to lower the threshold of application development.

From the perspective of operation, with the core goal of "liberating store clerks' energy and focusing on customer services", we have reduced manual repetitive labor work through automated procedures, helped stores operate in compliance, and enabled store clerks to devote more energy to customer services. In terms of new retail, based on consumer behavior data and market trends, customized strategic suggestions are generated to promote refined and intelligent operations. For the supply chain, we have established a demand warning system, optimized the intelligent restocking model, improved the accuracy of sales forecast, and improved both inventory efficiency and market responsiveness.

(2) Improvement of new retail business

Firstly, focus on the category leader + private brand (preferred by LBX) strategy, intensify the coordination of commercial procurement, improve the supply chain response efficiency and satisfaction with goods, and lower the out-of-stock rate. Secondly, accurately match the market demand through the refined operation of the business districts. Thirdly, AI algorithms empower human-machine collaboration to continuously optimize performance efficiency and customer experience. In the first quarter of 2026, the total sales of online channels (including franchises) exceeded RMB 828 million, representing a year-on-year increase of 10.4%. As at the end of the reporting period, the Company had a total of 12,321 stores with O2O delivery services, including 764 stores operating for 24 hours a day, and the service system was further improved.

6. Pharmaceutical retail companies with courage to innovate

(1) Deepening the reform of commercial procurement system and achieving stable results in cost reduction and efficiency enhancement

Firstly, take core products as the strategic anchor points of commercial procurement, and concentrate resources on building a cost-effective and competitive commodity matrix. As at the end of the reporting period, the Company had operated approximately 22,800 SKUs (product specifications), and the days sales of inventory during the reporting period were 90, which took the leading in the industry. Secondly, optimize channel integration and vertical management of procurement, and build a supply chain ecology that reduces costs, increases efficiency, and achieves mutual benefit and win-win results. In the first quarter, the Company's unified procurement sales accounted for 76.8%, representing a year-on-year increase of 1.5%. Thirdly, with the focus on consumers' health needs, continue to deepen our diversification strategies and build differentiated competitive advantages. Fourthly, strictly implement product replacement, focus on improving the efficiency of single products, and optimize the structure of private brands. During the reporting period, the sales of self-operated stores with private brands amounted to RMB 952 million, accounting for approximately 24.4% of the sales, representing a year-on-year increase of 1.1%.

(2) Leveraging the advantages of the store network and tapping into commercial insurance business growth

The Company cooperates with insurance companies, Internet hospitals, pharmaceutical companies and other supply and demand parties to provide health management solutions and comprehensive drug protection services for commercial health insurance customers. As at the end of the reporting period, more than 12,000 stores of the Company had enabled commercial insurance payment for business cooperation. With the aid of the store terminal network and member management platform, the Company promoted commercial health insurance products such as Huiminbao, outpatient insurance, accident health insurance and expired drug replacement insurance, so as to attract more customers to participate in commercial insurance plans and tap into business growth.

(3) Commencing "implementation of the talent management plan" to consolidate organizational capabilities

Firstly, the talent management system was completely launched, and the talent management was upgraded from "system construction" to "deep system cultivation". In the first quarter of 2026, 202 core cadres were subject to job rotation. Secondly, the construction of talent echelons was consolidated, and reserve talents were cultivated for core cadres through the mode of "substitution and rotation". In the first quarter, about 30 reserve talents were selected for four key positions, and about 10 people were trained by rotation.

(4) Making efforts for brand innovation and communication to reach target customer groups in multiple dimensions

Reach target customer groups in multiple dimensions to enhance brand awareness and reputation. In the first quarter, the total omni-channel exposure of the Company's brands exceeded 1 billion. The Company cooperated with 20 brands in co-branding, and the number of partner brands increased by 150% year-on-year. Based on the "official account + pharmacist IP" matrix, the Company continuously produced high-quality brand promotion videos, with more than 150,000 likes and retweets. In the first quarter of 2026, We Media Matrix brand exposure exceeded 62 million times.

(II) Explanation of Operating Data

1. Main business situation by industry

By industry	Operating income	Operating costs	Gross profit margin (%)	Increase or decrease in operating income compared with the previous year (%)	Increase or decrease in operating costs compared with the previous year (%)	YoY change in gross profit margin (percentage points)
Retail	4,523,867,860	2,823,044,207	37.60	1.27	2.59	-0.81
Franchise, alliance, and distribution	920,248,527	796,309,835	13.47	1.86	2.05	-0.16
Others	37,180,601	25,230,607	32.14	-42.37	-41.58	-0.92
Total	5,481,296,988	3,644,584,649	33.51	0.85	1.94	-0.71

Note: The decrease in the Company's gross profit margin was mainly attributable to the increase in the proportion of DTP sales resulting from the penetration of DTP (New Special Drug) policies into lower-tier markets and the acceleration of new product approvals, and the increase in the proportion of online retail sales resulting from the growth of online retail sales. The gross profit margin of offline retail net of DTP and online retail basically remained the same on a year-on-year basis.

2. Main business situation by product

By products	Operating income	Operating costs	Gross profit margin (%)	Increase or decrease in operating income compared with the previous year (%)	Increase or decrease in operating costs compared with the previous year (%)	YoY change in gross profit margin (percentage points)
Chinese and western patent medicine	4,393,809,569	3,053,405,214	30.51	0.52	2.53	-1.36
Chinese medicine	434,222,583	217,344,272	49.95	9.19	2.64	3.19
Non-pharmaceuticals	653,264,836	373,835,163	42.77	-1.97	-3.00	0.61
Total	5,481,296,988	3,644,584,649	33.51	0.85	1.94	-0.71

3. Main business situation by region

By Region	Operating income	Operating costs	Gross profit margin (%)	Increase or decrease in operating income compared with the previous year (%)	Increase or decrease in operating costs compared with the previous year (%)	YoY change in gross profit margin (percentage points)
Central China	2,366,409,987	1,531,779,399	35.27	3.85	3.96	-0.07

South China	246,129,446	159,738,465	35.10	-5.33	-6.48	0.80
North China	598,647,675	421,539,568	29.58	3.23	6.36	-2.07
East China	1,389,828,205	950,989,754	31.58	-4.16	-2.49	-1.17
Northwest China	880,281,675	580,537,463	34.05	1.60	3.78	-1.38
Total	5,481,296,988	3,644,584,649	33.51	0.85	1.94	-0.71

Note: Central China region includes: Hunan Province, Hubei Province, Jiangxi Province, Henan Province;
South China region includes: Guangdong Province, Guangxi Zhuang Autonomous Region;
North China region includes: Tianjin Municipality, Inner Mongolia Autonomous Region, Shanxi Province;
East China region includes: Zhejiang Province, Shanghai Municipality, Anhui Province, Jiangsu Province, Shandong Province;
Northwest China region includes: Shaanxi Province, Gansu Province, Ningxia Hui Autonomous Region, Guizhou Province.

4. Market layout

(1) As of March 31, 2026, the Company had owned 15,001 stores, including 9,622 direct-sale stores and 5,379 franchise stores. The overall distribution of the direct-sale stores during the reporting period is as follows:

Unit: Store

Region	End of 2025	January - March 2026	
		Net Increase	Closing
Central China	3,473	-59	3,414
South China	544	-1	543
North China	1,467	-19	1,448
East China	2,798	-19	2,779
Northwest China	1,450	-12	1,438
Total	9,732	-110	9,622

(2) The operating efficiency of the Company's directly-operated stores is as follows:

Store type (classified by average daily sales)	Number of stores (unit)	Store operating area (m ²)	Average daily sales per square meter (Yuan/m ²)
Flagship store	103	42,179	212.2
Large store	254	45,875	111.4
Small-medium mature store	9,265	914,316	38.8
Total	9,622	1,002,370	49.4

Note: The Company's revenue per available square meter increased by RMB 1.4/m² compared with the first quarter of 2025, and by RMB 1/m² compared with 2025, indicating that the operating quality of the Company's stores was gradually improved as a whole.

(3) The situation of directly-operated stores obtaining medical insurance qualifications is as follows:

During the reporting period, 8,965 of the Company's directly-operated stores obtained various "designated retail pharmacy for medical insurance" qualifications, with medical insurance stores accounting for 93.17%.

Region	Total Number of Stores	Number of stores with various medical insurance qualifications	Proportion of total stores
Central China	3,414	3,293	96.46%
South China	543	539	99.26%
North China	1,448	1,241	85.70%
East China	2,779	2,735	98.42%
Northwest China	1,438	1,157	80.46%
Total	9,622	8,965	93.17%

IV. Quarterly Financial Statements

(i) Type of Audit Opinion

Applicable Not Applicable

(ii) Financial Statements

Consolidated Balance Sheet

March 31, 2026

Prepared by: LBX Pharmacy Chain Joint Stock Company LBX Pharmacy Chain Joint Stock Company

Unit: RMB Currency: RMB Audit Type: Unaudited

Item	March 31, 2026	December 31, 2025
Current assets:		
Cash and bank balances	2,668,574,392	2,358,429,285
Deposit reservation for balance		
Funds lent		
Trading financial assets		
Derivative financial assets		
Notes receivable	76,492,280	58,033,940
Accounts receivable	1,988,459,862	2,107,724,650
Accounts receivable financing	5,612,871	5,612,871
Prepayments	156,940,056	127,750,815
Premiums receivable		
Reinsurance accounts receivable		
Reserves for reinsurance contract receivable		
Other receivables	183,273,385	215,188,071
Of which: interest receivable		
Dividends receivable		

Redemptory monetary capital for sale		
Inventories	3,633,610,108	3,652,252,469
Including: Data resources		
Contract assets		
Assets held for sale		
Non-current assets due within one year	48,626,732	41,225,587
Other current assets	256,399,342	264,435,192
Total current assets	9,017,989,028	8,830,652,880
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables	57,743,195	66,161,336
Long-term equity investments	82,256,455	81,283,270
Other equity instrument investments	36,252,923	35,768,123
Other non-current financial assets	6,963,496	6,963,496
Investment property	240,805,064	242,880,980
Fixed assets	1,319,050,353	1,348,308,487
Construction in progress	22,543,608	1,734,300
Productive biological assets		
Oil-and-gas assets		
Right-of-use assets	1,992,642,373	2,049,366,982
Intangible assets	780,081,997	802,566,730
Including: Data resources		
Development expenditures	22,977,031	14,773,607
Including: Data resources		
Goodwill	5,612,990,783	5,612,990,783
Long-term deferred expenses	577,012,855	609,448,600
Deferred income tax assets	129,396,895	133,973,303
Other non-current assets	8,530,627	8,530,627
Total non-current assets	10,889,247,655	11,014,750,624
Total assets	19,907,236,683	19,845,403,504
Current liabilities:		
Short-term loans	498,193,267	697,299,622
Borrowings from central bank		
Funds borrowed		
Trading financial liabilities		
Derivative financial liabilities		

Notes payable	4,986,734,658	5,008,269,907
Accounts payable	1,890,505,986	1,746,997,615
Advances from customers	19,126,718	16,853,246
Contract liabilities	173,320,877	217,575,573
Financial assets sold for repurchase		
Deposits from customers and other banks		
Receiving from vicariously traded securities		
Receiving from vicariously sold securities		
Payroll payable	357,999,538	455,209,144
Taxes and dues payable	137,060,564	152,684,505
Other payables	592,262,404	626,911,001
Of which: Interest payable		
Dividends payable		
Service charges and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	1,377,446,395	1,227,214,169
Other current liabilities	17,000,197	15,196,091
Total current liabilities	10,049,650,604	10,164,210,873
Non-current liabilities:		
Reserves for insurance contracts		
Long-term loans	1,316,087,068	1,434,968,318
Bonds payable		
Including: Preference shares		
Perpetual bonds		
Lease liabilities	1,198,766,728	1,204,831,000
Long-term payables		
Long-term employee compensation payable		
Provisions		
Deferred income	9,640,567	10,556,274
Deferred tax liabilities	34,642,127	34,744,543
Other non-current liabilities		
Total non-current liabilities	2,559,136,490	2,685,100,135
Total liabilities	12,608,787,094	12,849,311,008
Total owner's equity (or shareholder's equity):		

Paid-in capital (or capital stock)	758,890,236	758,890,236
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserve	1,694,612,672	1,694,612,672
Less: Treasury stock		
Other comprehensive income	15,231,092	15,231,092
Special reserve		
Surplus reserve	350,789,036	350,789,036
General risk reserve		
Undistributed profits	3,979,724,610	3,715,868,949
Total owner's equity (or shareholder's equity) attributable to parent company	6,799,247,646	6,535,391,985
Minority equity	499,201,943	460,700,511
Total owner's equity (or shareholder's equity)	7,298,449,589	6,996,092,496
Total liabilities and owner's equity (or shareholder's equity)	19,907,236,683	19,845,403,504

Principal of the Company: Xie Zilong Person in Charge of Accounting Work: Chen Lishan Person in Charge of Accounting Department: Shi Lei

Consolidated Income Statement

January - March 2026

Prepared by: LBX Pharmacy Chain Joint Stock Company LBX Pharmacy Chain Joint Stock Company

Unit: RMB Currency: RMB Audit Type: Unaudited

Item	First Quarter 2026	First Quarter 2025
I. Total operating income	5,481,296,988	5,435,220,089
Of which: Operating income	5,481,296,988	5,435,220,089
Interest income		
Premium earned		
Fee and commission income		
II. Total operating costs	5,110,519,821	5,088,365,773
Including: operating costs	3,644,584,649	3,575,169,042
Interest expense		
Fee and commission expense		
Refunded premiums		
Net claims paid		
Net provision for insurance liabilities		
Expenditures for policy dividends		
Reinsurance expenses		
Taxes and surcharges	20,339,349	19,606,254

Selling expenses	1,137,949,946	1,178,098,269
Administrative expenses	267,567,403	269,319,579
R&D expenses	12,094,832	8,405,207
Financial expenses	27,983,642	37,767,422
Including: Interest expenses		
Interest income		
Add: Other income	15,013,661	16,365,873
Investment income (loss indicated with "-")	980,027	1,710,371
Including: Income from investments in associates and joint ventures		
Gain on derecognition of financial assets measured at amortized cost		
Exchange gains (losses indicated with "-")		
Net gains (losses indicated with "-") on net investment hedges		
Gains from change in fair value (losses indicated with "-")		
Credit impairment loss (loss indicated with "-")	221,413	-172,263
Asset impairment loss (loss indicated with "-")	333,224	144,065
Gains from disposal of assets (losses indicated with "-")	-1,087,616	-757,855
III. Operating profits (loss indicated with "-")	386,237,876	364,144,507
Add: non-operating income	3,434,572	4,853,057
Less: non-operating expenses	3,866,041	2,769,204
IV. Profit before tax (Total loss indicated with "-")	385,806,407	366,228,360
Less: income tax expenses	83,449,314	78,503,678
V. Net Profit (Net loss indicated with "-")	302,357,093	287,724,682
(I) By operating continuity		
1. Net profit from ongoing operations (net loss indicated with "-")	302,357,093	287,724,682
2. Net profit from discontinued operations (net loss indicated with "-")		
(II) By ownership attribution		
1. Net profits attributable to the parent company's shareholders (net losses indicated with "-")	263,855,661	250,636,310

2. Minority interest (net loss indicated with "-")	38,501,432	37,088,372
VI. Net amount of other comprehensive income after tax		
(I) Other comprehensive income attributable to owners of the parent company, net of tax		
1. Other comprehensive income that will not be reclassified into profit or loss		
(1) Remeasurement changes in defined benefit plans		
(2) Other comprehensive income that cannot be carried over to profit or loss under equity method		
(3) Changes in the fair value of other equity instrument investments		
(4) Changes in the fair value of the enterprise's own credit risk		
2. Other comprehensive income that will be re-classified into profit or loss		
(1) Other comprehensive income under equity method that can be transferred to profit or loss		
(2) Changes in the fair value of other debt investment		
(3) Amount of financial assets reclassified into other comprehensive income		
(4) Credit impairment provision of other debt investments		
(5) Hedging reserve of cash flows		
(6) Translation differences of foreign currency financial statements		
(7) Others		
(II) Post-tax net amount of other comprehensive income attributable to minority shareholders		
VII. Total comprehensive income	302,357,093	287,724,682
(I) Total comprehensive income attributable to owners of the parent company	263,855,661	250,636,310
(II) Total comprehensive income attributable to minority shareholders	38,501,432	37,088,372

VIII. Earnings per share (EPS)		
(I) Basic earnings per share (RMB/share)	0.35	0.33
(II) Diluted EPS (RMB/share)	0.35	0.33

For business combinations involving enterprises under common control occurring during the period, the net profit realized by the combined party before the combination was: RMB 0, and the net profit realized by the combined party in the previous period was: RMB 0.

Principal of the Company: Xie Zilong Person in Charge of Accounting Work: Chen Lishan
Person in Charge of Accounting Department: Shi Lei

Consolidated Cash Flow Statement

January - March 2026

Prepared by: LBX Pharmacy Chain Joint Stock Company LBX Pharmacy Chain Joint Stock Company

Unit: RMB Currency: RMB Audit Type: Unaudited

Item	First Quarter 2026	First Quarter 2025
I. Cash flow from operating activities:		
Cash received from sales of goods and rendering of services	6,340,617,796	5,962,689,738
Net increase in deposits from customers and interbank		
Net increase in loans from the central bank		
Net increase in funds borrowed from other financial institutions		
Cash received from original insurance contract premiums		
Net cash received from reinsurance business		
Net increase in policyholder savings and investment funds		
Cash received from interest, fees, and commissions		
Net increase in borrowed funds		
Net increase in funds from repurchase agreements		
Net cash received from securities trading agency		
Refund of tax and levies	422,338	1,630,258
Other cash received relating to operating activities	141,666,227	164,568,300
Subtotal of cash inflows of operating activities	6,482,706,361	6,128,888,296
Cash paid for purchasing goods and receiving services	4,169,588,703	3,831,806,465

Net increase in customer loans and advances		
Net increase in deposits in the central bank and interbank		
Cash paid for original insurance contract claims		
Net increase in the lending funds		
Cash paid for interest, fees, and commissions		
Cash paid for policy dividends		
Cash paid to and for employees	923,136,396	957,930,913
Various tax payments	247,985,728	231,130,419
Other cash paid relating to operating activities	283,398,590	303,753,624
Subtotal of cash outflows from operating activities	5,624,109,417	5,324,621,421
Net cash flows from operating activities	858,596,944	804,266,875
II. Cash flows from investing activities:		
Cash received from return on investments	130,303	
Cash received from investment income	419,018	314,173
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	53,355	6,010,837
Net cash recovered from disposal of subsidiaries and other operating units	7,362,626	208,977
Other cash received relating to investing activities		
Subtotal of cash inflows of investing activities	7,965,302	6,533,987
Cash paid for acquisition and construction of fixed assets, intangible assets and other long-term assets	37,165,632	56,789,500
Cash paid for investment	5,040	412,961
Net increase in pledge loans		
Net cash paid for acquisition of subsidiaries and other business entities		202,500
Other cash paid relating to investing activities		550,000
Subtotal of cash outflows from investing activities	37,170,672	57,954,961

Net cash flows from investing activities	-29,205,370	-51,420,974
III. Cash flows from financing activities:		
Cash received from capital contributions		
Including: cash received by subsidiaries from minority shareholders		
Cash received from loans	100,000,000	5,590,000
Other cash received related to financing activities		
Subtotal of cash inflows of financing activities	100,000,000	5,590,000
Cash paid for repayment of debts	221,110,278	460,324,535
Cash paid for distributing dividends and profits or repaying interest	7,812,561	32,694,593
Including: dividends and profits paid by subsidiaries to minority shareholders		23,419,644
Other cash paid relating to financing activities	294,714,378	314,592,760
Subtotal of cash outflows from financing activities	523,637,217	807,611,888
Net cash flows from financing activities	-423,637,217	-802,021,888
IV. Effect of exchange rate changes on cash and cash equivalents		
V. Net increase in cash and cash equivalents	405,754,357	-49,175,987
Add: opening balance of cash and cash equivalents	1,143,841,378	986,735,653
VI. Closing balance of cash and cash equivalents	1,549,595,735	937,559,666

____ Principal of the Company: Xie Zilong Person in Charge of Accounting Work: Chen Lishan
Person in Charge of Accounting Department: Shi Lei _____

(iii) First-time adoption of new accounting standards or interpretations, etc., in 2026 involving adjustment of the financial statements at the beginning of the first year of adoption

Applicable Not Applicable

This announcement is hereby made.

Board of Directors of LBX Pharmacy Chain Joint Stock Company
April 22, 2026